When Gilead Sciences Inc. President John Milligan recently told Wall Street analysts that he expected more stories centering on the growing number of patients benefitting from the company’s pricey hepatitis C drug Sovaldi, he wasn’t kidding.
New hepatitis C treatments, including Foster City-based Gilead’s $1,000-a-pill cure, could save the lives of tens of thousands of people, concludes a report released last week by the California Healthcare Institute. But the report doesn’t address pricing of Gilead’s drug, Sovaldi, or oncoming hep C drugs or the impact of those drugs on government and private insurance programs.
Help employers find you! Check out all the jobs and post your resume.
